Back to Search

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

River Forest, Illinois, 60305
Columbus, Georgia, 31904
New Orleans, Louisiana, 70115
Lakeland, Florida, 33805
Miami, Florida, 33186
Search open until 11/28/2024

The main purpose of this first-in-human study is to generate sufficient safety and immunogenicity data to enable the selection of an appropriate dose level for the initiation of a Phase 2/3 study.

Eligibility

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical

Ages Eligible for Study Min Age: 50 years - Max Age: N/A
Sexes Eligible for Study All
Accepts Healthy Volunteers Yes

Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Tuscaloosa, Alabama and more
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Neurobehavioral Disinhibition Read more
Palo Alto, California and more
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Solid Tumor, Adult and more Read more
Hollywood, Florida and more
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
Epstein-Barr Virus Infection Read more